PL372803A1 - Przeciwciała monoklonalne przeciw ludzkiej tenascynie - Google Patents

Przeciwciała monoklonalne przeciw ludzkiej tenascynie

Info

Publication number
PL372803A1
PL372803A1 PL03372803A PL37280303A PL372803A1 PL 372803 A1 PL372803 A1 PL 372803A1 PL 03372803 A PL03372803 A PL 03372803A PL 37280303 A PL37280303 A PL 37280303A PL 372803 A1 PL372803 A1 PL 372803A1
Authority
PL
Poland
Prior art keywords
monoclonal antibody
human tenascin
tenascin monoclonal
human
antibody
Prior art date
Application number
PL03372803A
Other languages
English (en)
Other versions
PL213216B1 (pl
Inventor
Santis Rita De
Anna Maria Anastasi
Original Assignee
Sigma-Tau Industrie Farmaceutiche Riunite, S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma-Tau Industrie Farmaceutiche Riunite, S.P.A. filed Critical Sigma-Tau Industrie Farmaceutiche Riunite, S.P.A.
Publication of PL372803A1 publication Critical patent/PL372803A1/pl
Publication of PL213216B1 publication Critical patent/PL213216B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL372803A 2002-02-26 2003-02-20 Przeciwcialo monoklonalne, sposób jego wytwarzania, jego zastosowanie, wytwarzajaca je linia komórek hybrydoma, pojemnik je zawierajacy, zestaw terapeutyczny, DNA kodujacy przeciwcialo, wektor zawierajacy DNA, komórki gospodarza zawierajace wektor i kompozycja farmaceutyczna PL213216B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35929902P 2002-02-26 2002-02-26

Publications (2)

Publication Number Publication Date
PL372803A1 true PL372803A1 (pl) 2005-08-08
PL213216B1 PL213216B1 (pl) 2013-01-31

Family

ID=27766061

Family Applications (1)

Application Number Title Priority Date Filing Date
PL372803A PL213216B1 (pl) 2002-02-26 2003-02-20 Przeciwcialo monoklonalne, sposób jego wytwarzania, jego zastosowanie, wytwarzajaca je linia komórek hybrydoma, pojemnik je zawierajacy, zestaw terapeutyczny, DNA kodujacy przeciwcialo, wektor zawierajacy DNA, komórki gospodarza zawierajace wektor i kompozycja farmaceutyczna

Country Status (19)

Country Link
US (3) US7438908B2 (pl)
EP (1) EP1478667B1 (pl)
JP (1) JP4488746B2 (pl)
KR (1) KR101048894B1 (pl)
CN (1) CN1317303C (pl)
AR (1) AR038700A1 (pl)
AT (1) ATE480564T1 (pl)
AU (1) AU2003215900B2 (pl)
BR (1) BR0307994A (pl)
CA (1) CA2475395C (pl)
CY (1) CY1111108T1 (pl)
DE (1) DE60334076D1 (pl)
DK (1) DK1478667T3 (pl)
ES (1) ES2352180T3 (pl)
MX (1) MXPA04008216A (pl)
PL (1) PL213216B1 (pl)
PT (1) PT1478667E (pl)
SI (1) SI1478667T1 (pl)
WO (1) WO2003072608A1 (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20040105A1 (it) * 2004-02-27 2004-05-27 Tecnogen Scpa Anticorpo monoclonale antitenascina umana.
RU2009107707A (ru) 2006-08-04 2010-09-10 Новартис АГ (CH) СПЕЦИФИЧНОЕ К EphB3 АНТИТЕЛО И ЕГО ПРИМЕНЕНИЕ
WO2009086197A1 (en) 2007-12-20 2009-07-09 Monogram Biosciences, Inc. Her-2 diagnostic methods
FR2930036B1 (fr) * 2008-04-11 2010-05-07 Assist Publ Hopitaux De Paris Procede de diagnostic d'une hypertension arterielle pulmonaire.
WO2010002862A2 (en) * 2008-07-01 2010-01-07 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (fgfr3) binding proteins
EP2438442B1 (en) 2008-12-01 2017-08-09 Laboratory Corporation of America Holdings Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95
BRPI1007321A2 (en) 2009-01-15 2018-07-10 Laboratory Corporation Of America Holdings methods for measuring and / or quantifying the presence and / or amount of her-3 or her-3 in a complex in a patient sample, and to determine if an individual with cancer is likely to respond to treatment with a targeted therapy. and antibody.
US20100233732A1 (en) * 2009-01-15 2010-09-16 Laboratory Corporation Of America Holdings Methods of Determining Patient Response By Measurement of HER-2 Expression
US10266585B2 (en) 2009-08-28 2019-04-23 The Board Of Regents Of The Univerity Of Texas System Methods of treating brain injury
US20120269814A1 (en) * 2009-11-10 2012-10-25 Amgen Inc. Anti-c mpl antibodies
CA2817973C (en) 2010-10-15 2019-06-25 The Board Of Regents Of The University Of Texas System Antibodies that bind amyloid oligomers
US8959638B2 (en) 2011-03-29 2015-02-17 Mcafee, Inc. System and method for below-operating system trapping and securing of interdriver communication
US8966624B2 (en) 2011-03-31 2015-02-24 Mcafee, Inc. System and method for securing an input/output path of an application against malware with a below-operating system security agent
US9038176B2 (en) 2011-03-31 2015-05-19 Mcafee, Inc. System and method for below-operating system trapping and securing loading of code into memory
US8925089B2 (en) 2011-03-29 2014-12-30 Mcafee, Inc. System and method for below-operating system modification of malicious code on an electronic device
US8863283B2 (en) 2011-03-31 2014-10-14 Mcafee, Inc. System and method for securing access to system calls
US9087199B2 (en) 2011-03-31 2015-07-21 Mcafee, Inc. System and method for providing a secured operating system execution environment
US9032525B2 (en) 2011-03-29 2015-05-12 Mcafee, Inc. System and method for below-operating system trapping of driver filter attachment
US9317690B2 (en) 2011-03-28 2016-04-19 Mcafee, Inc. System and method for firmware based anti-malware security
US9262246B2 (en) 2011-03-31 2016-02-16 Mcafee, Inc. System and method for securing memory and storage of an electronic device with a below-operating system security agent
US8813227B2 (en) 2011-03-29 2014-08-19 Mcafee, Inc. System and method for below-operating system regulation and control of self-modifying code
US8966629B2 (en) 2011-03-31 2015-02-24 Mcafee, Inc. System and method for below-operating system trapping of driver loading and unloading
US9255595B2 (en) * 2011-04-29 2016-02-09 Bae Systems Information And Electronic Systems Integration Inc. Optical dome bezel
EP2791686B1 (en) * 2011-12-12 2017-02-15 Oxford University Innovation Limited Tenascin-c and use thereof in rheumatoid arthritis
CA2904357C (en) 2013-03-15 2020-09-22 Intrinsic Lifesciences Llc Anti-hepcidin antibodies and uses thereof
GB201414021D0 (en) * 2014-08-07 2014-09-24 Nascient Ltd Biological materials and uses thereof
CA2961917A1 (en) 2014-09-22 2016-03-31 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
GB201602413D0 (en) * 2016-02-10 2016-03-23 Nascient Ltd Method

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4687732A (en) 1983-06-10 1987-08-18 Yale University Visualization polymers and their application to diagnostic medicine
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
AU6445894A (en) 1993-03-19 1994-10-11 Duke University Method of treatment of tumors with an antibody binding to tenascin
US5482698A (en) 1993-04-22 1996-01-09 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin polymer conjugates
US5820858A (en) 1993-05-28 1998-10-13 The Scripps Research Institute Methods and compositions for inhibiting CD14 mediated cell activation
US6335014B1 (en) * 1998-06-17 2002-01-01 The Institute Of Physical And Chemical Research Medicament for suppressing cancer metastasis
ITRM20020128A1 (it) 2002-03-08 2003-09-08 Sigma Tau Ind Farmaceuti Dimeri di avidina efficaci nell'incrementare la concentrazione di biotina radioattiva nella immunoterapia con "pretargeting".

Also Published As

Publication number Publication date
AU2003215900B2 (en) 2008-09-25
EP1478667B1 (en) 2010-09-08
CN1317303C (zh) 2007-05-23
HK1078589A1 (en) 2006-03-17
KR20040086426A (ko) 2004-10-08
US7438908B2 (en) 2008-10-21
CA2475395C (en) 2011-08-02
DK1478667T3 (da) 2010-12-20
ATE480564T1 (de) 2010-09-15
US20040005643A1 (en) 2004-01-08
WO2003072608A1 (en) 2003-09-04
CN1639192A (zh) 2005-07-13
MXPA04008216A (es) 2004-11-26
AR038700A1 (es) 2005-01-26
US20110020219A1 (en) 2011-01-27
EP1478667A1 (en) 2004-11-24
JP2005534615A (ja) 2005-11-17
ES2352180T3 (es) 2011-02-16
CY1111108T1 (el) 2015-06-11
JP4488746B2 (ja) 2010-06-23
CA2475395A1 (en) 2003-09-04
PL213216B1 (pl) 2013-01-31
PT1478667E (pt) 2010-12-09
US20050106145A1 (en) 2005-05-19
BR0307994A (pt) 2004-12-07
KR101048894B1 (ko) 2011-07-13
AU2003215900A1 (en) 2003-09-09
US8048417B2 (en) 2011-11-01
DE60334076D1 (de) 2010-10-21
SI1478667T1 (sl) 2010-12-31

Similar Documents

Publication Publication Date Title
DK1478667T3 (da) Monoklonalt anti-humant tenascin-antistof
AU2003264009A8 (en) Humanized rabbit antibodies
IL156030A0 (en) Humanized antibodies
AU1174702A (en) Humanized anti-lt-beta-r antibodies
EP1592776A4 (en) HIGH AFFINE ANTI-HUMAN-IGE ANTIBODIES
AU2003217912A8 (en) Antibody optimization
IL202348A0 (en) Anti-her2 antibody variants
EP1494693A4 (en) SPECIFIC ANTIBODIES TO CRIPTO
PL375405A1 (pl) Przeciwciała
EP1567555A4 (en) HUMANIZED ANTIBODIES AGAINST CHEMOTOXIC MONOCYTE PROTEINS
AU2003220079A8 (en) Uses of monoclonal antibody 8h9
PL1718678T3 (pl) Przeciwciało monoklonalne przeciw ludzkiej tenascynie
AU2003229799A1 (en) Novel humanized anti-vap-1 monoclonal antibody
FI20011055L (fi) Heveiiniä sitovat monoklonaaliset vasta-aineet
GB0226878D0 (en) Antibodies
GB0415644D0 (en) Monoclonal antibody
GB0121727D0 (en) Monoclonal antibodies
IL165753A0 (en) Humanized monoclonal antibody nPAM4
GB0003359D0 (en) Monoclonal antibodies
GB0008160D0 (en) Monoclonal antibodies
GB0030139D0 (en) Monoclonal antibody
GB0029846D0 (en) Monoclonal antibody
GB0200933D0 (en) Phenotyping antibodies
GB0020794D0 (en) Humanised antibodies
AU2001254858A1 (en) Anti-D monoclonal antibodies